Suscribirse

Development, validity, and reliability of the Japanese version of the 7C of vaccination readiness scale - 30/03/23

Doi : 10.1016/j.ajic.2022.07.001 
Masaki Machida, MD, PhD a, b, , Takako Kojima, MA c, Helena Akiko Popiel, PhD c, Mattis Geiger, PhD d, Yuko Odagiri, MD, PhD a, Shigeru Inoue, MD, PhD a
a Department of Preventive Medicine and Public Health, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan 
b Department of Infection Prevention and Control, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan 
c Center for International Education and Research, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan 
d Department of Implementation Research, Health Communication Working Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany 

Address correspondence to Masaki Machida, MD, PhD, Department of Preventive Medicine and Public Health, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.Department of Preventive Medicine and Public HealthTokyo Medical University6-1-1 ShinjukuShinjuku-kuTokyo160-8402Japan

Highlights

The Japanese version of 7C of the vaccination readiness scale was developed.
The validity and reliability of the Japanese scale were assessed.
The Japanese version of the scale showed acceptable validity and reliability.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

The 7C of the vaccination readiness scale measures the 7 psychological components that structure people's vaccination readiness. We aimed to develop the Japanese version of this scale (7C scale Japanese version) and to assess its validity and reliability.

Methods

The full and short versions of 7C scale Japanese were developed based on translation guidelines provided by the ISPOR Task Force. An Internet survey, including 709 participants, was performed to assess the scale's validity and reliability within a confirmatory factor analysis (CFA) framework (men: 38.8%, age range: 20-92 years). Invariance analysis using multiple-group CFA was conducted to test cross-cultural validity between participants in this study and those in the 7C original version study. McDonald's omega and intraclass correlation coefficient were calculated to evaluate internal consistency and test-retest reliability, respectively. To clarify the criterion validity, regression analysis, with previous COVID-19 vaccination status as the dependent variable, was performed to calculate pseudo R2.

Results

The 7C scale Japanese version exhibited good content validity, structural validity, configural invariance, and criterion validity. The results showed good internal consistency, and test-retest reliability, except for the “calculation” component.

Conclusions

7C scale Japanese version exhibited acceptable reliability and validity; however, “calculation” may be a less reliable subscale.

El texto completo de este artículo está disponible en PDF.

Key Words : Vaccine hesitancy, Vaccine acceptance, Measurement, Questionnaire

List of abbreviations : COVID-19, 7C scale, 7C scale Japanese version, COSMIN, 7C scale original version, CFA, CFI, TLI, RMSEA, SRMR, MGCFA, ICC


Esquema


 Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
 Conflict of interests: The authors declare that they have no competing interests.
 Authors’ contributions: M.M. and S.I. contributed to the study conception and design. M.M., T.K., H.A.P., M.G., Y.O. and S.I. designed the questionnaire. M.M., and S.I. collected and analyzed the data. M.M. wrote the first draft of the manuscript. All authors were involved in the review of previous versions of the manuscript. All authors have read and approved the final manuscript.
 Ethics approval and consent to participate: This study was approved by the Ethics Committee of Tokyo Medical University, Tokyo, Japan (no.: T2021-0265). Informed consent was obtained from all respondents.
 Data availability: The datasets used and/or analyzed in this study are available from the corresponding author on reasonable request.


© 2022  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 51 - N° 4

P. 426-433 - avril 2023 Regresar al número
Artículo precedente Artículo precedente
  • Healthcare workers’ presenteeism causing an outbreak of respiratory infections in a facility for patients with severe motor and intellectual disabilities
  • Naoki Takayama, Haruyo Sakaki, Masahiro Shirai, Atsushi Toyoda, Hiroko Takayanagi, Kazuya Takagi, Kaoru Fujita, Eiko Endo
| Artículo siguiente Artículo siguiente
  • Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA
  • Mélanie T. Mahoney, Hunter V. Brigman, Brian D. Johnston, James R. Johnson, Elizabeth B. Hirsch

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.